Incannex Healthcare (IXHL) said Wednesday it has completed patient dosing in the phase 2 portion of its phase 2/3 study of IHL-42X in obstructive sleep apnea.
Incannex shares rallied more than 700% in recent trading.
The company said it expects to conclude end-of-study follow-up assessments by May 17, with topline data anticipated in July.
Incannex also said it is preparing for a meeting with the US Food and Drug Administration ahead of the data readout to discuss results and steps toward a new drug application submission.
The company said phase 3 trial planning is underway and will be conducted at US sites to improve operational efficiency.
Incannex said it has started to engage in preliminary commercial discussions amid "growing interest" in the IHL-42X program.
Price: 0.74, Change: +0.66, Percent Change: +768.70
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。